What changed in the March 10, 2026 CAPR analyst rating?

H.C. Wainwright on **March 10, 2026** reiterated a **Buy** on Capricor (CAPR) and kept a **$60** price target. The CAPR analyst rating was maintained rather than upgraded or downgraded.

Does the maintained CAPR analyst rating mean immediate upside?

Not necessarily. A maintained **CAPR analyst rating** signals analyst confidence but not guaranteed short-term gains. Investors often wait for clinical or regulatory catalysts to confirm analyst expectations.

How does the CAPR analyst rating affect investor strategy?

Use the **CAPR analyst rating** as one factor. Combine it with Capricor’s upcoming catalysts, cash position, and your risk profile before acting. Analysts’ ratings guide but do not dictate trades.

What is Meyka AI’s view on the CAPR analyst rating?

Meyka AI notes the maintained **CAPR analyst rating** is supportive and assigns CAPR a **B+** grade based on benchmark and sector metrics. This is informational and not investment advice.

Analyst Ratings

H.C. Wainwright Maintains Buy on Capricor Therapeutics, Inc. (CAPR) Mar 2026

ByHuzaifa Zahoor March 11, 2026

On March 10, 2026 H.C. Wainwright maintained a Buy on Capricor Therapeutics, Inc. (CAPR), a clear signal for investors watching small-cap biotech. The CAPR analyst rating remained a Buy with a $60 price target cited in market coverage. We note this action came as the stock moved -4.49% (-$1.57) since the firm’s last commentary. This maintained rating keeps H.C. Wainwright as the primary active analyst covering CAPR